Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial
Published inCancer, vol. 128, no. 16, p. 3067-3079
Publication date2022-08-15
First online date2022-06-21
Abstract
Keywords
- Atezolizumab
- Immune checkpoint inhibitors
- Immunotherapy
- Inflammation
- Lung cancer
- Neutrophil to lymphocyte ratio (NLR)
- Non-small cell lung cancer (NSCLC)
- B7-H1 Antigen / metabolism
- Carcinoma, Non-Small-Cell Lung / drug therapy
- Carcinoma, Non-Small-Cell Lung / genetics
- Cell-Free Nucleic Acids
- DNA Helicases
- Docetaxel
- ErbB Receptors / metabolism
- Humans
- Immunologic Factors
- Immunotherapy
- Inflammation
- Kelch-Like ECH-Associated Protein 1
- Lung Neoplasms / drug therapy
- Lung Neoplasms / genetics
- Lung Neoplasms / metabolism
- Male
- NF-E2-Related Factor 2
- Nuclear Proteins
- Prognosis
- Proto-Oncogene Proteins p21(ras)
- Transcription Factors
Affiliation
Funding
- Wellcome Trust - [PS3416]
Citation (ISO format)
CORTELLINI, Alessio et al. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. In: Cancer, 2022, vol. 128, n° 16, p. 3067–3079. doi: 10.1002/cncr.34348
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:167313
- DOI : 10.1002/cncr.34348
- PMID : 35727053
ISSN of the journal0008-543X